The splicing factor RBM25 controls MYC activity in acute myeloid leukemia
Research output: Contribution to journal › Journal article › Research › peer-review
- The splicing factor RBM25 controls MYC activity in acute myeloid leukemia
Final published version, 1 MB, PDF document
Cancer sequencing studies have implicated regulators of pre-mRNA splicing as important disease determinants in acute myeloid leukemia (AML), but the underlying mechanisms have remained elusive. We hypothesized that "non-mutated" splicing regulators may also play a role in AML biology and therefore conducted an in vivo shRNA screen in a mouse model of CEBPA mutant AML. This has led to the identification of the splicing regulator RBM25 as a novel tumor suppressor. In multiple human leukemic cell lines, knockdown of RBM25 promotes proliferation and decreases apoptosis. Mechanistically, we show that RBM25 controls the splicing of key genes, including those encoding the apoptotic regulator BCL-X and the MYC inhibitor BIN1. This mechanism is also operative in human AML patients where low RBM25 levels are associated with high MYC activity and poor outcome. Thus, we demonstrate that RBM25 acts as a regulator of MYC activity and sensitizes cells to increased MYC levels.
|Number of pages||14|
|Publication status||Published - 2019|
Number of downloads are based on statistics from Google Scholar and www.ku.dk